The antibacterial drug candidate known as SM1B74 was developed by researchers at NYU Grossman School of Medicine in New York City and Janssen Biotech. Researchers describe it as an “anti-S.aureus monoclonal antibody-centryin fusion protein” that works in part by dodging 10 of the pathogen’s disease-causing strategies, though without killing it — indicating a promising approach to address antibiotic resistance.
The drug candidate also reduced bacterial loads in the kidneys of infected mice when combined with small doses of the antibiotic vancomycin.
Read more here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
